Ani Pharmaceuticals (ANIP) Intangibles (2012 - 2026)

Ani Pharmaceuticals has disclosed Intangibles across 15 years of filings, most recently posting $449.9 million for Q2 2026.

• In Q2 2026, Intangibles fell 13.54% year-over-year to $449.9 million; the TTM figure through Jun 2026 stood at $449.9 million (down 13.54% YoY), while the FY2025 annual figure was $479.5 million, down 11.5% from the prior year.
• Intangibles came in at $449.9 million for Q2 2026 at Ani Pharmaceuticals, down from $467.2 million in the prior quarter.
• In the past five years, Intangibles ranged from a high of $569.8 million in Q3 2024 to a low of $183.1 million in Q2 2024.
• Average Intangibles over 5 years is $409.6 million, with a median of $489.7 million recorded in 2025.
• Year-over-year, Intangibles jumped 198.28% in 2022 and plunged 61.37% in 2024.
• Over 5 years, Intangibles stood at $251.6 million in 2022, then dropped by 16.94% to $209.0 million in 2023, then jumped by 159.24% to $541.8 million in 2024, then declined by 11.5% to $479.5 million in 2025, then fell by 6.19% to $449.9 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $449.9 million in Q2 2026, $467.2 million in Q1 2026, and $479.5 million in Q4 2025.